We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (CARNEBI)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 17, 2007
Last Update Posted: September 16, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Centro Cardiologico Monzino

The investigators test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Condition Intervention Phase
Chronic Heart Failure Drug: carvedilol Drug: bisoprolol Drug: Nebivolol Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function

Resource links provided by NLM:

Further study details as provided by Centro Cardiologico Monzino:

Primary Outcome Measures:
  • exercise capacity [ Time Frame: two months ]

Secondary Outcome Measures:
  • lung diffusion [ Time Frame: two months ]

Enrollment: 60
Study Start Date: July 2007
Study Completion Date: May 2010
Arms Assigned Interventions
Active Comparator: Carvedilol Drug: carvedilol
Active Comparator: Bisoprolol Drug: bisoprolol
Active Comparator: Nebivolol Drug: Nebivolol


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

  • No comorbidity
  • NYHA class IV
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00517725

Centro Cardiologico Monzino, University of Milan
Milan, Italy, 20138
Sponsors and Collaborators
Centro Cardiologico Monzino
Principal Investigator: Piergiuseppe Agostoni, MD, PhD Centro Cardiologico Monzino
Study Chair: Giancarlo Marenzi, MD Centro Cardiologico Monzino
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Piergiuseppe Agostoni, Centro Cardiologico Monzino - Univeristy of Milan
ClinicalTrials.gov Identifier: NCT00517725     History of Changes
Other Study ID Numbers: R76-CCM S78/407
First Submitted: August 16, 2007
First Posted: August 17, 2007
Last Update Posted: September 16, 2010
Last Verified: September 2010

Keywords provided by Centro Cardiologico Monzino:
lung diffusion
heart failure

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists